PT-141 Research for Female Sexual Dysfunction
An evidence-based overview of research examining PT-141 in the context of female sexual dysfunction. This page synthesizes findings from peer-reviewed literature.
Research Summary
PT-141 is specifically FDA-approved for female hypoactive sexual desire disorder, making it one of few pharmacological options for this condition. The drug targets desire rather than arousal. The mechanism involves melanocortin receptor activation affecting dopaminergic signaling in sexual motivation circuits. This represents a novel therapeutic approach for FSAD. Vyleesi (bremelanotide) is administered by autoinjector subcutaneously. Use is limited to 8 doses per month due to potential for blood pressure effects with frequent dosing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. PT-141 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.